|
1
|
Sun J, Zheng G, Gu Z and Guo Z: MiR-137
inhibits proliferation and angiogenesis of human glioblastoma cells
by targeting EZH2. J Neurooncol. 122:481–489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Zhao S and Xu Z: Network and
pathway analysis of microRNAs, transcription factors, target genes
and host genes in human glioma. Oncol Lett. 11:3534–3542.
2016.PubMed/NCBI
|
|
3
|
Lefranc F, Rynkowski M, DeWitte O and Kiss
R: Present and potential future adjuvant issues in high-grade
astrocytic glioma treatment. Adv Tech Stand Neurosurg. 34:3–35.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q
and Tao R: MicroRNA-205 functions as a tumor suppressor in human
glioblastoma cells by targeting VEGF-A. Oncol Rep. 27:1200–1206.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
7
|
Dykxhoorn DM: MicroRNAs and metastasis:
Little RNAs go a long way. Cancer Res. 70:6401–6406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ciafrè SA, Galardi S, Mangiola A, Ferracin
M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moller HG, Rasmussen AP, Andersen HH,
Johnsen KB, Henriksen M and Duroux M: A systematic review of
microRNA in glioblastoma multiforme: Micro-modulators in the
mesenchymal mode of migration and invasion. Mol Neurobiol.
47:131–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu X, Cui Y, Yang S, Xu Y and Zhang Z:
MicroRNA-613 inhibited ovarian cancer cell proliferation and
invasion by regulating KRAS. Tumour Biol. 37:6477–6483. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao Q, Li J, Yan J, Liu S, Guo Y, Chen D
and Luo Q: Lycium barbarum polysaccharides ameliorates renal injury
and inflammatory reaction in alloxan-induced diabetic nephropathy
rabbits. Life Sci. 157:82–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Qi M, Li S, Qi T, Mei H, Huang K,
Zheng L and Tong Q: microRNA-9 targets matrix metalloproteinase 14
to inhibit invasion, metastasis, and angiogenesis of neuroblastoma
cells. Mol Cancer Ther. 11:1454–1466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim KJ, Li B, Winer J, Armanini M, Gillett
N, Phillips HS and Ferrara N: Inhibition of vascular endothelial
growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature. 362:841–844. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Plate KH, Breier G, Weich HA and Risau W:
Vascular endothelial growth factor is a potential tumour
angiogenesis factor in human gliomas in vivo. Nature. 359:845–848.
1992. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chaudhry IH, O'Donovan DG, Brenchley PE,
Reid H and Roberts IS: Vascular endothelial growth factor
expression correlates with tumour grade and vascularity in gliomas.
Histopathology. 39:409–415. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Varlet P, Guillamo JS, Nataf F, Koziak M,
Beuvon F and Daumas-Duport C: Vascular endothelial growth factor
expression in oligodendrogliomas: A correlative study with
Sainte-Anne malignancy grade, growth fraction and patient survival.
Neuropathol Appl Neurobiol. 26:379–389. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maisonpierre PC, Suri C, Jones PF,
Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J,
Aldrich TH, Papadopoulos N, et al: Angiopoietin-2, a natural
antagonist for Tie2 that disrupts in vivo angiogenesis. Science.
277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang D, Qiu C, Zhang H, Wang J, Cui Q and
Yin Y: Human microRNA oncogenes and tumor suppressors show
significantly different biological patterns: From functions to
targets. PLoS One. 5(pii): e130672010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kota J, Chivukula RR, O'Donnell KA,
Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P,
Torbenson M, Clark KR, et al: Therapeutic microRNA delivery
suppresses tumorigenesis in a murine liver cancer model. Cell.
137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bader AG, Brown D and Winkler M: The
promise of microRNA replacement therapy. Cancer Res. 70:7027–7030.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao XM, Liu KQ, Zhu G, He F, Duval B,
Richer JM, Huang DS, Jiang CJ, Hao JK and Chen L: Identifying
cancer-related microRNAs based on gene expression data.
Bioinformatics. 31:1226–1234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao R, Feng J and He G: miR-613 regulates
cholesterol efflux by targeting LXRa and ABCA1 in PPARγ activated
THP-1 macrophages. Biochem Biophys Res Commun. 448:329–334. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong D, Zhang Y, Zeng YJ, Gao M, Wu GZ,
Hu CJ, Huang G and He FT: MicroRNA-613 represses lipogenesis in
HepG2 cells by downregulating LXRa. Lipids Health Dis. 12:322013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren W, Li C, Duan W, Du S, Yang F, Zhou J
and Xing J: MicroRNA-613 represses prostate cancer cell
proliferation and invasion through targeting Frizzled7. Biochem
Biophys Res Commun. 469:633–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li D, Li DQ, Liu D and Tang XJ: MiR-613
induces cell cycle arrest by targeting CDK4 in non-small cell lung
cancer. Cell Oncol (Dordr). 39:139–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li B, Xie Z, Li Z, Chen S and Li B:
MicroRNA-613 targets FMNL2 and suppresses progression of colorectal
cancer. Am J Transl Res. 8:5475–5484. 2016.PubMed/NCBI
|
|
31
|
Qiu W, Yang Z, Fan Y and Zheng Q:
MicroRNA-613 inhibits cell growth, migration and invasion of
papillary thyroid carcinoma by regulating SphK2. Oncotarget.
7:39907–39915. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu H, Duan P, Zhu H and Rao D: miR-613
inhibits bladder cancer proliferation and migration through
targeting SphK1. Am J Transl Res. 9:1213–1221. 2017.PubMed/NCBI
|
|
33
|
Scheuer W, Thomas M, Hanke P, Sam J, Osl
F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, et
al: Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a
tetravalent bispecific antibody (TAvi6) targeting VEGF-A and
angiopoietin-2. MAbs. 8:562–573. 2016. View Article : Google Scholar : PubMed/NCBI
|
